Poland—Full of Potential
In the past five years, the Polish government has begun to recognize the potential of biotech with several initiatives to help new companies. It also established NewConnect, the alternative market of the Warsaw Stock Exchange, in 2007.
“With Poland’s entry to the EU, we have had access to more funding and expertise, and the Warsaw Stock Exchange is now the second most active market in Europe for IPOs.
“That coupled with Poland having a pool of talented yet underexploited scientists and a balanced economy with little debt means that unlike many other countries, we have the room for growth and investment,” commented Przewiezlikowski.
Even Poland’s most well-established pharmaceutical company, Polpharma, has in the past year begun to set up a separate biotech division at the Gdansk Science and Technology Park called Polpharma Biologics.
“Polpharma Biologics intends to be fully operational by 2012, with process development as well as a cGMP scale-up facility, which will allow manufacturing of clinical batches of our biological products,” said Piotr Lassota, Ph.D., scientific director of Polpharma Biologics.
“This is why we are recruiting now at the BioForum. We will have a staff of 45 scientists and supporting personnel developing and making biosimilars, as well as innovative products to treat cancer and CNS disorders. We plan to in-license some biological products at various stages of development to complement our portfolio.”
This new air of optimism in Poland has helped spawn a number of promising biotechs. These include Selvita, Proteon Pharmaceuticals and Mabion.